Senecavirus A T-cell Epitope Polypeptide Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Senecavirus A (SVA) do not effectively stimulate cellular immunity, which is crucial for controlling SVA infection, and there is a lack of understanding regarding T-cell epitopes for SVA.
Innovation Solution
Identification and screening of T-cell immune antigenic epitopes from conserved non-structural proteins 2C and 3AB of SVA, leading to the development of a T-cell epitope polypeptide that can efficiently induce an SVA-specific immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If inactivated vaccines are used, then the vaccine is safe and easy to produce, but cellular immune response is weak and protection is insufficient
Solution Approach 1:
The patent segments the viral proteome into specific T-cell epitope peptides (2C-5, 2C-6, 2C-7, 2C-8, 2C-9, 2C-10, 2C-12, 2C-14, 2C-15; 3AB-35, 3AB-38) that are independently identified and synthesized. This segmentation allows the vaccine to focus on specific immunogenic regions rather than using the entire inactivated virus, thereby maintaining safety while enhancing cellular immune response and protection effectiveness.
Solution Approach 2:
The patent changes the parameter of vaccine composition from whole inactivated virus to specific peptide sequences. By altering the molecular composition parameter and focusing on conserved T-cell epitopes, the vaccine achieves stronger cellular immunity and complete protection while maintaining production ease and safety.
2Reliability
If attenuated vaccines are used, then cellular immune response is strong, but the vaccine is more complex to produce and may have safety concerns
Solution Approach 1:
The patent extracts and isolates specific T-cell epitope peptides from the SVA proteome through bioinformatics analysis and experimental verification. By taking out only the essential immunogenic peptides (2C and 3AB regions) rather than using the entire attenuated virus, the vaccine achieves strong cellular immune response while simplifying production and eliminating safety concerns associated with attenuated virus cultivation.
Solution Approach 2:
The patent creates synthetic peptide copies of the conserved T-cell epitopes through chemical synthesis. These synthetic peptide copies replicate the immunogenic properties of the native viral proteins without requiring live or attenuated virus, thereby achieving strong cellular immunity with simplified production processes and enhanced safety.
3Ease of manufacture
If structural proteins are used for immunization, then the vaccine is easy to produce, but T-cell immune response is not adequately stimulated
Solution Approach 1:
Instead of using whole structural proteins that are easy to produce but fail to stimulate T-cells, the patent inverts the approach by identifying and using specific T-cell epitope peptides from nonstructural proteins (2C and 3AB). This inversion of the traditional vaccine strategy prioritizes T-cell stimulation over ease of production, achieving complete protection through targeted peptide immunization.
Data Source
AI summary
A T-cell epitope polypeptide of Senecavirus A (SVA) having an amino acid sequence represented by one of SEQ ID NOs: 1-7: SEQ ID NO: 1:DEALGRVLTPAAVDEALVDL;SEQ ID NO: 2:AILAKLGLALAAVTPGLIIL;SEQ ID NO: 3:KASPVLQYQL;SEQ ID NO: 4:EMKKLGPVAL;SEQ ID NO: 5:AHDAFMAGSG;SEQ ID NO: 6:PPLGDDQIEYLQVLKSLALT;andSEQ ID NO: 7:LASTLIAQAVSKRLYGSQSV.